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Rheumatoid arthritis and osteoarthritis: disease 
pathogenesis
Rheumatoid arthritis (RA) is a chronic inﬂ  ammatory 
disease characterized by the activation of synovial tissue 
lining the joint capsule, which results in the invasion of 
the cartilage and bone leading to the progressive joint 
dysfunction [1]. Severe morbidity and structural damage 
of joints caused by chronic inﬂ  ammation often lead to 
major personal, family, and ﬁ  nancial consequences, as 
well as increased mortality. Recent understanding of the 
RA pathogenesis has clariﬁ  ed the role of cytokines and 
other inﬂ  ammatory mediators in this process and has 
provided a scientiﬁ  c rationale in the process of develop-
ing targeted therapies [2].
Osteoarthritis (OA) is a common disorder of synovial 
joints characterized pathologically by focal areas of 
damage to the articular cartilage, centered on load-bearing 
areas, which is associated with new bone formation at the 
joint margins (osteophytosis), changes in the subchondral 
bone, variable degrees of mild synovitis, and thickening 
of the joint capsule [3]. Th   e severity of OA diﬀ  ers from 
patient to patient, but the very common clinical 
symptoms include pain, reduced range of motion, inﬂ  am-
mation, and deformity [4]. Th   is condition is strongly age 
related, being less common before the age of 40 but 
showing a marked increase in frequency with age [3]. 
Although OA is considered the disease of the destruc  tion 
of articular cartilage, recent evidence suggests that it may 
also damage bone and synovium in the arthritic joints 
[3,4]. Despite existing evidence of the crosstalk between 
tissues at the cellular and molecular levels, however, 
intertwined pathophysiological processes causing OA 
have reduced the focus in choosing from one of these 
three tissues – articular cartilage, bone, or synovium – to 
serve as the key therapeutic target [3].
Treatment of arthritis: approaches and options
Conventional disease-modifying anti-rheumatic drugs 
such as methotrexate have long been the mainstay of RA 
treatment and are still advocated as a ﬁ  rst-line option in 
newly diagnosed RA patients [5]. While a combination of 
good eﬃ   cacy and acceptable toxicity, in conjunction with 
low cost and patient convenience, has made methotrexate 
an increasingly favored drug for RA, recent studies 
suggest that patients lose eﬃ   cacy over time and only a 
minority of them achieve disease remission from its use 
[5]. TNFα inhibitors, as ﬁ  rst-generation biologics, have 
radically changed the treatment of patients with refrac-
tory RA. Among patients with RA who are unresponsive 
to methotrexate, however, only two-thirds respond to 
TNFα inhibitors – which opened the option of combi  na-
tion therapy (combining disease-modifying anti-rheu-
matic drugs with biological therapy) [5,6]. As a result, 
newer approaches have resulted in the development of 
next-generation biologics during the past few years, 
including abatacept, rituximab, and tocilizumab [2,6].
Pharmacological management of OA includes analgesics 
and nonsteroidal anti-inﬂ  ammatory drugs. Unfortunately, 
these medications can precipitate severe adverse reactions 
while providing only symptomatic relief from pain and no 
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addition, increased rates of cardiovascular events asso-
ciated with cyclooxygenase-2 (COX-2) inhibitors and 
some conventional nonsteroidal anti-inﬂ  ammatory drugs 
have made the treatments inappropriate for long-term use 
by OA patients with high risk of heart disease or stroke [8]. 
More recent emerging data from clinical trials conducted 
over nine clinical centers in the United States underlined 
the clinical eﬃ     cacy of a glucosamine and chondroitin 
sulfate combination on the progressive loss of cartilage, 
pain, and stiﬀ  ness in patients with knee OA [7].
Plant-derived molecules for the treatment of 
arthritis
Th  e past decade or two have seen a dramatic increase 
and growing interest in the use of alternative treatments 
and herbal therapies by arthritis patients [9-11]. Trust-
worthy documentation of traditional knowledge, together 
with extensive modern scientiﬁ  c/pharmaco  logical experi-
mentation, however, is necessary to validate or refute the 
purported medicinal value. In this regard, epigallo-
catechin-3-gallate (EGCG) has in the past decade been 
extensively evaluated by us and other researchers for its 
potential anti-rheumatic activity using in vitro experi-
men  tations and animal models of arthritis. Th  e  following 
section of the present review highlights some of these 
major ﬁ  ndings and puts forward an argument for the 
future development of EGCG as a potential thera  peutic 
entity for rheumatic diseases.
Epigallocatechin-3-gallate
Green tea (Camellia sinensis) is one of the most 
commonly consumed beverages in the world and is a rich 
source of polyphenols known as catechins (30 to 36% of 
dry weight) including EGCG, which constitutes up to 
63% of total catechins [12]. EGCG has been shown to be 
25 to 100 times more potent than vitamins C and E in 
terms of antioxidant activity [13]. A cup of green tea 
typically provides 60 to 125 mg catechins, including 
EGCG [14].
Effi   cacy of EGCG in arthritis
In vitro fi  ndings
Cartilage/chondrocyte protection
Extensive studies in the past decade have veriﬁ  ed the 
cartilage-preserving and chondroprotective action of 
EGCG. We pioneered research in this therapeutic area 
and studied the beneﬁ  ts of EGCG on progressive carti-
lage degradation, a hallmark of OA, using chondrocytes 
derived from OA cartilage. Proinﬂ  ammatory cytokines 
such as IL-1β, TNFα, and IL-6 have been shown to 
modulate extracellular matrix turnover, to accelerate the 
degradation of cartilage, and to induce apoptosis in 
chondrocytes [3,4].
Besides promoting imbalance between excessive carti-
lage destruction and cartilage repair processes, IL-1β has 
been a potent inducer of reactive oxygen species, 
including nitric oxide and inﬂ  ammatory mediators such 
as prostaglandin E2, via enhanced expression of the 
enzymes inducible nitric oxide synthase and COX-2, 
respectively [15,16]. Preincubation of human chondro-
cytes derived from OA cartilage at diﬀ  erent micromolar 
concentrations of EGCG showed a marked inhibition in 
the IL-1β-induced inducible nitric oxide synthase and 
COX-2 expression and activity, which further resulted in 
the reduced nitric oxide and prostaglandin E2 synthesis 
[15,16]. Deﬁ  ning the molecular mechanism of EGCG’s 
eﬃ     cacy in regulating inducible nitric oxide synthase 
expression, the results showed that EGCG inhibits IL-1β-
induced phosphorylation and proteasomal degradation 
of IκBα to suppress NF-κB nuclear translocation [16].
In a follow-up study to determine the eﬀ  ect of EGCG 
on other signaling pathways triggered by IL-1β, Singh 
and colleagues showed that EGCG selectively inhibited 
the p46 isoform of c-Jun-N-terminal kinase induced by 
IL-1β [17]. Th   is resulted in the reduced accumulation of 
phosphorylated c-Jun and activation protein-1 DNA 
binding activity, and of activation protein-1-mediated 
inﬂ  ammatory responses in OA chondrocytes.
Under normal circumstances, chondrocytes in the 
cartilage make extracellular matrix components such as 
aggrecan and type II collagen as required in response to 
mechanical pressure [3]. Under abnormal or diseased 
conditions, however, chondrocyte metabolism is altered 
under the inﬂ  uence of the increased inﬂ  ux of pro  inﬂ  am-
matory cytokines that activate matrix-degrading enzymes 
termed matrix metalloproteinases (MMPs) and of reac-
tive mediators that promote cartilage degradation [18]. 
MMPs are a large group of enzymes that play a crucial 
role in tissue remodeling as well as in the destruction of 
cartilage in arthritic joints due to their ability to degrade a 
wide variety of extracellular matrix components [19,20]. 
Interestingly, the collagenases among the MMP family 
are of particular importance in joint disorders due to 
their ability to eﬃ   ciently cleave type II collagen [19,20].
In another study, we evaluated the potential of EGCG 
to protect human cartilage explants from IL-1β-induced 
release of cartilage matrix proteoglycans and the induc-
tion and expression of MMP-1 and MMP-13 in human 
chondrocytes [21]. Our results showed that EGCG 
pretreatment of cultured human OA chondro  cytes 
signiﬁ   cantly inhibited the expression and activities of 
MMP-1 and MMP-13 in a dose-dependent manner [21]. 
In a parallel observation, another study found that 
catechins from green tea inhibited the degradation of 
human cartilage proteoglycan and type II collagen, and 
selectively inhibited ADAMTS-1, ADAMTS-4, and 
ADAMTS-5 [22,23]. Further evaluation of the eﬀ  ect of 
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that EGCG ameliorates IL-1β-mediated suppression of 
transforming growth factor β synthesis, and enhances 
type II collagen and aggrecan core protein synthesis in 
human articular chondrocytes [24]. Th  ese results were 
further supported by a recent study showing the protec-
tive eﬀ  ect of EGCG on advanced glycation end product-
induced MMP-13 production in human OA chondro-
cytes in vitro [25].
To further support the chondroprotective eﬀ  ects  of 
EGCG in arthritis, a recent study conducted by the 
biomaterial testing group on collagen showed that 
collagen preincubated with EGCG demonstrated a 
remark  able resistance against degradation by bacterial 
collagenase and MMP-1 [26]. A circular dichroism 
spectral analysis of the triple-helical structure of EGCG-
treated collagen and untreated collagen showed a higher 
free-radical scavenging activity in EGCG-treated collagen 
[26]. Recent studies evaluating the cartilage-preserving 
property of EGCG showed that articular cartilages, 
preserved in a storage solution containing EGCG for up 
to 4 weeks, showed a higher degree of chondrocyte 
viability and proteoglycan (GAG) content of the extra-
cellular matrix, at least in part, by reversibly regulating 
the cell cycle at the G0/G1 phase and NF-κB expression 
[27,28]. Th  ese ﬁ  ndings provide a scientiﬁ  c rationale for 
the eﬃ   cacy of EGCG in protecting cartilage breakdown 
during the progress of joint disorders and could be 
utilized in other chronic ailments where integrity of the 
collagen is compromised in tissue destruction or 
remodeling.
Bone-preserving activity
In rheumatic diseases, loss of the intricate balance 
between bone formation and bone resorption activity 
leads to skeletal abnormalities that aﬀ  ect the quality of 
life [29]. In particular, three TNF family molecules – the 
receptor activator of NF-κB, its ligand RANKL, and the 
decoy receptor of RANKL, osteoprotegerin – have estab-
lished their pivotal role as central regulators of osteoclast 
development and osteoclast function [29]. In 2006 Hafeez 
and colleagues showed that green tea poly  phenols 
triggered caspase-3-dependent apoptosis in these cells by 
regulating the constitutively active NF-κBp65 to induce 
DNA fragmentation and apoptosis in osteocarcoma 
SaOS-2 cells [30]. Another recent study using human 
osteoblastic cells evaluated the eﬀ   ect of EGCG on 
oncostatin M-induced monocyte chemotactic protein-1 
(MCP-1)/CCL2 synthesis [31]. Th   e  experi men tal  ﬁ  ndings 
of the study suggested that EGCG inhibits oncostatin M-
induced MCP-1/CCL2 synthesis in human osteoblastic 
and MG-63 cells by reducing c-Fos synthesis [31].
IL-6 – produced by both stromal cells and osteoblasts 
in response to several stimuli such as lipopolysaccharides, 
IL-1β, and TNFα – stimulates bone resorption and osteo-
clast formation [32,33]. Th  e eﬃ     cacy of EGCG was 
evaluated against basic ﬁ   broblast growth factor-2-
induced IL-6 synthesis in osteoblast-like MC3T3-E1 cells 
[34]. EGCG inhibited basic ﬁ  broblast growth factor-2-
induced IL-6 synthesis dose dependently and, in part, via 
suppression of ERK1/2 and p38 mitogen-activated 
protein kinase pathways in osteoblast cells [34]. Further 
extending these ﬁ  ndings, a recent study by Kamon and 
colleagues showed that EGCG reduced osteoclast 
formation in these cells by inhibiting osteo  blast diﬀ  er-
entiation without aﬀ  ecting their viability and prolifera-
tion [35]. Another recent study addressing the precise 
molecular mechanism through which EGCG inhibits 
osteoblast diﬀ  erentiation showed that EGCG produced 
an anti-osteoclastogenic eﬀ   ect by inhibiting RANKL-
induced activation of c-Jun-N-terminal kinase and NF-
κB pathways, thereby suppressing the gene expression of 
c-Fos and NFATc1 in osteoclast precursors [36].
Regulation of synovial fi  broblast activity
Under normal physiological conditions, synovial ﬁ  bro-
blasts form a thin lining of synovial tissue surrounded by 
the ﬁ  brous capsule of the joint. Th  e lining of synovial 
ﬁ  broblasts secretes synovial ﬂ  uid, which has both lubri-
cat  ing and immunomodulatory properties, and which 
promotes normal joint function. In diseased conditions 
such as RA, synovial ﬁ   broblasts in the RA synovium 
become hyperproliferative and secrete factors that 
promote inﬂ  ammation, neovascularization, and cartilage 
degradation.
In response to cytokines produced by macrophages 
such as TNFα and IL-1β, RA synovial ﬁ  broblasts secrete 
matrix-degrading enzymes such as MMPs, ADAMTS, 
and cathepsins. MMPs released from RA synovial 
ﬁ   broblasts can modulate activity of cytokines and 
chemo  kines, release proapoptotic ligands from cell sur-
faces, and promote ﬁ  broblast invasion of the cartilage. 
RA synovial ﬁ  broblasts also attract leukocytes by expres-
sing chemokines in response to cytokines via distinct 
signaling pathway, which provides an opportunity to 
target them for diﬀ  erent therapeutic approaches.
We and other workers have extensively evaluated the 
eﬃ   cacy of EGCG using the synovial ﬁ  broblasts isolated 
from human joints to provide the exact mechanism 
through which EGCG inhibits or suppresses arthritis. 
Our study showed that EGCG pretreatment signiﬁ  cantly 
inhibited both the constitutive and IL-1β-induced chemo-
kine MCP-1/CCL2 production, regulated upon activa-
tion, normal T-cell expressed and secreted (RANTES/
CCL5) production, growth-regulated oncogene (Gro-α/
CXCL1) production, and epithelial neutrophil-activating 
peptide 78 (ENA-78/CXCL5) production, and MMP-2 
activation by RA synovial ﬁ   broblasts [37]. Th  is was 
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induced protein kinase Cδ and NF-κB pathways. One 
step further, we found that EGCG signiﬁ  cantly inhibited 
MMP-2 activity induced by RANTES/CCL5, Gro-α/
CXCL1, and ENA-78/CXCL5, suggesting a novel 
mechanism of MMP-2 regulation by EGCG in RA 
synovial ﬁ   broblasts [37]. In our follow-up study, we 
observed a similar inhibitory eﬀ  ect of EGCG-containing 
green tea extract (GTE) on chemokine synthesis in RA 
synovial ﬁ  broblasts [38]. GTE preincubation surprisingly 
induced the basal and IL-1β-induced chemokine receptor 
expression in these cells, however, which was also 
mimicked by the protein kinase Cδ inhibitor, Rottlerin 
[38]. Further studies are underway to clarify the 
signiﬁ  cance of these ﬁ  ndings in relation to GTE’s anti-
arthritic property.
It has also been shown that EGCG was eﬀ  ective in 
inhibiting IL-1β-induced MMP-1, MMP-3, and MMP-13 
in human tendon ﬁ  broblasts [39]. Synovial ﬁ  broblast IL-6 
production has been shown to inhibit bone formation 
and to concomitantly stimulate bone resorption and 
pannus formation [40]. In this regard, we showed in our 
recent study that EGCG pretreatment inhibits IL-1β-
induced IL-6 and vascular endothelial growth factor 
synthesis in RA synovial ﬁ   broblasts [41]. In a recent 
study, Yun and colleagues showed that EGCG treatment 
resulted in dose-dependent inhibition of TNFα-induced 
production of MMP-1 and MMP-3 at the protein and 
mRNA levels in RA synovial ﬁ   broblast by inhibiting 
activation protein-1 DNA binding activity [42].
In RA, the purposeful induction of apoptosis in activated 
synovial ﬁ  broblasts has emerged as a thera  peutic strategy 
for halting deleterious tissue growth [1]. Th  e  constitutive 
activation of survival protein Akt and NF-κB in RA 
synovial ﬁ   broblasts makes these cells resis  tant to both 
TNFα-mediated and Fas-mediated apoptosis [43,44]. In 
recent years, studies have linked the over  expression of the 
anti-apoptotic myeloid cell leukemia-1 (Mcl-1) protein as a 
major cause of RA synovial ﬁ   broblast resistance to 
apoptosis [1,45]. Our recent study to evaluate the eﬃ   cacy 
of EGCG in downregulating Mcl-1 expression showed 
that, in RA synovial ﬁ  broblasts, EGCG inhibits constitutive 
and TNFα-induced Mcl-1 protein expression [46]. 
Importantly, EGCG speciﬁ   cally abrogated Mcl-1 
expression in RA synovial ﬁ  broblasts and aﬀ  ected Mcl-1 
expression to a lesser extent in OA synovial ﬁ  broblasts, 
normal synovial ﬁ  broblasts, and endo  thelial cells. In this 
study, caspase-3 activation by EGCG also suppressed RA 
synovial ﬁ  broblast growth, and this eﬀ  ect was mimicked 
by Akt and NF-κB inhibitors. Interestingly, Mcl-1 degrada-
tion by EGCG sensitized RA synovial ﬁ  broblasts to TNFα-
induced cleavage of poly ADP-ribose poly  merase protein 
and apoptosis. Our ﬁ   nding suggests that EGCG may 
selectively induce apoptosis and further sensitize RA 
synovial ﬁ  broblasts to TNFα-induced apoptosis to regulate 
their invasive growth in RA.
Animal studies
Collagen-induced arthritis
Th  e potential disease-modifying eﬀ   ect of EGCG on 
arthritis was ﬁ   rst discovered in a study in which the 
consumption of EGCG-containing GTE in drinking 
water ameliorated collagen-induced arthritis (CIA) in 
mice [47]. Th  e reduced CIA incidence and severity was 
reﬂ   ected in a marked inhibition of the inﬂ  ammatory 
mediators COX-2, IFNγ, and TNFα in arthritic joints of 
green tea-fed mice. Additionally, total immunoglobulins 
(IgG) and type II collagen-speciﬁ  c IgG levels were found 
to be lower in serum and arthritic joints of green tea-fed 
mice [47].
Interestingly, some recent pharmacological studies 
using EGCG or green tea to suppress arthritis have 
focused equally on bone resorption observed in RA 
[31,48-51]. A recent study by Morinobu and colleagues 
showed that EGCG treatment reduced bone resorption 
as determined by tartrate-resistant acid phosphatase-
positive multinucleated cells, bone resorption activity, 
and osteoblast-speciﬁ  c gene expression of the transcrip-
tion factor NF-ATc1, but not of NF-κB, c-Fos, and c-Jun 
[49]. Th  e  in vivo eﬀ  ect of osteoclast diﬀ  erentiation in CIA 
mice was not clear, however, as intraperitoneal adminis-
tration of EGCG (20 mg/kg) inhibited inﬂ  ammation in 
experimental arthritis [49]. Using in vivo testing con-
ducted in mouse CIA model, another study showed that 
EGCG (20 mg/kg, intraperitoneally daily) ameliorated 
arthritis and macrophage inﬁ   ltration, and caused a 
reduction in the amount of MCP-1/CCL2-synthesizing 
osteoblasts [31].
Adjuvant-induced arthritis
Recent advances in understanding the pathogenic eﬀ  ects 
of IL-6 provide evidence of its central role in promoting 
acute inﬂ  ammation [32,33]. Further studies related to the 
mechanisms through which EGCG inhibits inﬂ  ammation 
and tissue destruction in RA were studied by us and 
others. Our novel ﬁ  ndings showed that EGCG selectively 
inhibits IL-6 synthesis in rat adjuvant-induced arthritis, 
thus providing a missing link to the reduction in inﬂ  am-
mation observed in earlier studies [41]. Administration of 
EGCG (100 mg/kg, intraperitoneally daily) during the 
onset of arthritis in rats resulted in a speciﬁ  c inhibition of 
IL-6 levels in the serum and joints of EGCG-treated 
animals. Our study also showed that EGCG enhances the 
synthesis of soluble gp130 protein, an endogenous 
inhibitor of IL-6 signaling and trans-signaling [41]. Th  e 
inhibition of arthritis in EGCG-treated rats correlated to 
the reduction in MMP-2 activity in the joints compared 
with the activity level in arthritic rats [41].
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activity of GTE in arthritis showed that GTE adminis-
tration in drinking water ameliorated rat adjuvant-
induced arthritis via the inhibition of serum IL-17 levels, 
with a concomitant upregulation of serum IL-10 levels 
[52]. In our recent study, a daily per oral adminis  tration 
of GTE (200 mg/kg) modestly ameliorated rat adjuvant-
induced arthritis, which was accompanied by a decrease 
in MCP-1/CCL2 and GROα/CXCL1 levels and enhanced 
CCR-1, CCR-2, CCR-5, and CXCR1 receptor expression 
in the joints of GTE-administered rats [38]. Th  is  suggests 
that chemokine receptor overexpression with reduced 
chemokine production by GTE may be one potential 
mechanism to limit the overall inﬂ  ammation and joint 
destruction in RA. Further studies may be designed to 
improve the clinical outcome in animal models of RA 
through modiﬁ  cation of the dose and frequency of GTE 
administration, which may provide a better outcome and 
beneﬁ  ts of GTE in RA.
Clinical studies
Th  e  eﬃ   cacy of EGCG or GTE in human RA or OA using 
the phase-controlled trials is yet to be tested. Several 
phase I and phase II cancer chemoprevention trials, 
however, have been performed using EGCG or GTE. A 
study by Elmets and colleagues showed that EGCG 
provided photoprotection to the skin from ultraviolet 
radiation on topical application in healthy human 
volunteers [53]. In another study, patients suﬀ  ering from 
chronic lymphocytic leukemia showed an improvement 
in their clinical, laboratory, and radiographic outcomes 
and objective responses [54] after oral ingestion of 
EGCG. Th  e results of a recent open-label, phase II 
clinical trial using EGCG in prostate cancer patients 
showed a signiﬁ   cant decrease in the serum levels of 
prostate-speciﬁ  c antigen, hepatocyte growth factor, and 
vascular endothelial growth factor after 6 weeks of 
treatment [55]. A phase I trial on EGCG, with a 400 to 
2,000 mg dose taken by mouth twice a day for month, 
was well tolerated by chronic lymphocytic leukemia 
patients, the majority of whom showed a decline in 
lymphocyte count and lymphadenopathy [56]. Th  is has 
encouraged the investigators of the study to initiate a 
phase II trial to evaluate EGCG eﬃ   cacy using a 2,000 mg 
dose twice daily [56].
Th  e eﬃ   cacy of EGCG in human metabolic disorders 
has been a topic of clinical interest. A randomized, 
controlled clinical trial using EGCG on insulin resistance 
and associated metabolic risk factors in obese men 
showed that 400 mg EGCG treatment twice daily for 
8  weeks showed no eﬀ   ect on insulin sensitivity or 
secretion and glucose tolerance, but caused a moderate 
reduction in blood pressure and a positive eﬀ  ect  on 
mood [57]. In another study by Maki and colleagues, the 
consumption of 625  mg EGCG-containing catechins 
daily for 12 weeks caused a greater loss of body weight 
and a decrease in the fasting serum triglyceride levels in 
the catechin-administered group [58]. In a double-blind, 
placebo-controlled trial, intake of GTE (containing 
302  mg EGCG) for 12  weeks showed a signiﬁ  cant 
reduction in the levels of low-density lipoprotein and 
triglyceride, and markedly increased the high-density 
lipoproteins and adiponectin levels [59].
EGCG: bioavailability and possible drug 
interactions
Pharmacokinetics of EGCG
Th  e pharmacokinetics and bioavailability of EGCG in 
rodents and humans is well studied. An acute and short-
term toxicity study on EGCG preparations showed that 
the dietary consumption of EGCG by rats for 13 weeks 
was nontoxic at doses up to 500 mg/kg/day [60]. A study 
by Chen and colleagues showed that administration of 
pure EGCG or EGCG in the form of decaﬀ  einated GTE 
to rats via intravenous or intragastric administration 
showed diﬀ   erences in the pharmacokinetic patterns, 
favoring the intravenous route when given as an extract 
[61]. Studies also revealed that EGCG possesses a longer 
half-life and a smaller clearance rate, suggesting a slower 
rate of elimination of EGCG as compared with 
epigallocatechin and epi  catechin [61]. A study by Kim 
and colleagues, in which subjects consumed GTE at 0.6% 
in drinking water over 28 days, showed that EGCG is 
more available in free form as compared with other 
catechins [62]. Th   ese studies also showed that the highest 
concen  tration of EGCG was found in the large intestine, 
suggesting a higher absorption rate but less clearance – 
as demonstrated by the lower levels of EGCG detected in 
plasma and distributed in the kidney, liver, lungs, and 
prostate of rats [61,62]. In contrast to the results with 
rats, however, the level of EGCG in mice was much 
higher than that of epigallocatechin and epicatechin, 
suggesting a high bioavailability of EGCG in mice [62]. In 
addition, it was reported that the intraperitoneal 
administration of green tea containing EGCG showed 
much higher tissue and plasma concentration of EGCG 
than that obtained intragastrically [62]. Although other 
chemical processes such as peracetylation and glucuroni-
dation have been shown to enhance the bioavailability of 
EGCG, not much is known about the distribution and its 
bioactivity in diseased conditions.
In humans, EGCG has been extensively studied for its 
acute and long-term toxicity studies [63-66]. A standard-
ized capsule of polyphenon E containing 400 mg, 800 mg, 
or 1,200  mg EGCG was used to study the pharmaco-
kinetics of EGCG in humans [63,64]. Th  e  pharmaco  kinetic 
analysis from the study showed that the average plasma 
area under the curve, the maximum concentration, and 
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given in the capsules of 400 mg, 800 mg, and 1,200 mg 
EGCG [64]. Th  is study also showed that administration 
of EGCG capsules to human subjects under fasting 
conditions signiﬁ   cantly enhanced the pharmacokinetic 
proﬁ   le and bioavailability of EGCG, possibly due to 
reduced conversion by glucuronidation process [64]. A 
4-week clinical study carried out to determine the safety 
and pharmacokinetics of EGCG at doses of 400 and 
800 mg/day in healthy participants showed no signiﬁ  cant 
adverse eﬀ  ects, and investigators observed a signiﬁ  cant 
(>60%) increase in EGCG bioavailability by the 
800 mg/day dose, when compared with the 400 mg/day 
dose, in these participants [63]. Th  ere are, however, 
limited numbers of studies suggesting that the EGCG 
plasma concentration may reach up to ~1  μM when 
consumed by drinking green tea [67,68]. Further studies 
are required to optimize the circulating and synovial 
concentrations of EGCG to avail beneﬁ  ts similar to those 
observed in vitro and in preclinical studies.
Drug interaction
Th  ere have been limited data available to validate or 
reject the potential beneﬁ   t of EGCG in RA patients. 
Studies conducted recently, however, evaluate the eﬃ   cacy 
of EGCG in combination with conventional medicine, 
which could be extrapolated for possible interaction with 
anti-rheumatic drugs. Th   e initial observation came from 
the anti-cancer studies using EGCG, wherein the 
administration of EGCG was shown to enhance the 
apoptosis-inducing property of COX-2 inhibitors on the 
growth of human prostate cancer cells in vitro and in vivo 
[69]. In another related study, EGCG sensitized human 
prostate carcinoma LNCaP cells to TNF-related apoptosis-
inducing ligand-induced apoptosis and synergistic 
inhibition of the biomarkers of angiogenesis and meta-
stasis [70]. Similar outcomes on the sensitization of RA 
synovial ﬁ  broblasts for TNF-related apoptosis-inducing 
ligand-induced apoptosis were observed with trichostatin 
A, suggesting a common mechanism of regulating 
invasive growth of synovial tissue in RA [71].
Another unique mechanism through which EGCG 
leaves a positive impact as a potential therapeutic option 
comes from its property of inducing pretranscriptional 
modiﬁ  cation, termed alternative splicing. In addition to 
our study, where EGCG enhanced the synthesis of soluble 
gp130 at least in part by this mechanism, recent reports 
suggest that EGCG modulates alternative splicing to 
correct mutated proteins to normal forms, as observed 
for survival motor neuron-1 protein in neurodegenerative 
disorder, or to produce spliced variants of Mcl-1 and Bcl-
X proteins in combination with ibuprofen that may 
inhibit the functionality of these anti-apoptotic proteins 
in prostate cancer cells [41,72,73]. More recently, 
conﬂ  icting results have emerged from the studies related 
to the eﬀ   ect of EGCG on clinical eﬃ   cacy  of  the 
chemotherapeutic agent Bortezomib as a proteasome 
inhibitor in cancer-related studies [74,75]. More 
elaborative and rigorous studies are awaited, however, to 
verify the possible interaction of EGCG with current 
treatment modalities for rheumatic diseases – in 
particular, biological therapies and metho  trexate 
treatment.
Development of synthetic analogs of EGCG: future 
implications
Th  e growing interest of pharmacologists in studying 
EGCG was never hidden from medicinal chemists, which 
led to the development of synthetic analogs of EGCG 
[76]. Zaveri and colleagues reported the synthesis of a 
trimethoxybenzoyl ester (D-ring) analog of EGCG, which 
was found to be equally as potent as natural EGCG for its 
eﬃ   cacy as an anti-carcinogenic agent [77]. In addition, 
there have been some recent eﬀ   orts to enhance its 
bioavailability by delivering EGCG using lipid nano-
capsules and liposome encapsulation, suggesting the 
possibility of this molecule being developed further by 
medicinal chemists [78]. In this direction, there has been 
a successful in vitro and in vivo testing of delivering 
EGCG in polylactic acid–polyethylene glycol nano-
particles to inhibit angiogenesis and induce apoptosis 
[79]. Similarly, the results from a recent study suggest 
that nanolipidic EGCG particles signiﬁ  cantly improved 
the neuronal α-secretase enhancing ability and possessed 
the oral bioavailability more than twofold over free 
EGCG for the treatment of Alzheimer’s disease [80].
Conclusions and future implications
Th   e present review summarizes the translational research 
for the validation of the purported beneﬁ  ts of EGCG in 
preclinical and clinical settings. An extensive evaluation 
of the potential risks or beneﬁ  ts of using EGCG alone or 
together with anti-rheumatic drugs may open a new area 
of research wherein EGCG or its synthetic analogs could 
be developed to enhance its clinical appeal. Extensive 
research on the beneﬁ   ts of EGCG in other chronic 
ailments such as carcinogenesis and cardiovascular 
diseases using clinical trials has shown promise [81,82]. 
With the availability of the safety proﬁ  le  and 
pharmacokinetics of EGCG in phase I trials in humans, 
the window of opportunity is even wider to test EGCG 
for its potential therapeutic eﬃ   cacy as an anti-rheumatic 
entity in human RA or OA. In conclusion, for the 
scientists and clinicians in the research area of drug 
discovery, EGCG represents a much safer molecule 
worth testing in humans, as the positive outcomes of 
such studies may have potential for its rapid clinical 
development and application.
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